Differences

This shows you the differences between two versions of the page.

--- home:arf:timeline [02.14.2019] – [Notes and comments] sallieq
+++ home:arf:timeline [02.14.2019] – [Notes and comments] sallieq
@@ Line 8: / Line 8: @@
 **1981** – While a Visiting Scientist in the Dept. of Surgery at Toronto's Hospital for Sick Children, Marshall sees IBM's presentation of a few nano-seconds of life of a humulin molecule (synthetic human insulin). The presentation is one of the first //in silico// models.
-**1984** - Marshall's PhD thesis in the [[www.library.uwa.edu.au|University of Western Australia]]  reveals the interest in mathematical modeling of human disease which would guide his research two decades later.
+**1984** - Marshall's PhD thesis "Modelling and simulation in diabetes care" in the [[www.library.uwa.edu.au|University of Western Australia]]  reveals the interest in mathematical modeling of human disease which would guide his research two decades later.
 **1986** – Standing in a city square in Stockholm, nearly the most northerly capital in the World, Marshall's body reacts badly to sunshine. [[home:lifestyle:light:physics_of_light#latitude|He realizes]] that his sensitivity goes beyond anything medicine had envisioned, and that vitamin D must in some way be associated with chronic disease.
@@ Line 17: / Line 17: @@
 **1999** – Marshall learns that other patients with sarcoidosis who were administered Angiotensin Receptor Blockers (ARBs) often developed a neurological reaction. Marshall starts a sabbatical in early 2001 in order to further investigate this reaction.
-**2001** - Marshall submits paper explaining that sarcoidosis could have a bacterial pathogenesis. Three revisions of the paper are rejected by the journal //[[http://www.sarcoidosis.it/home.html|Sarcoidosis, Vasculitis and Diffuse Lung Diseases]]// as having no potential interest for its readers.
+**2001** - Marshall submits paper explaining that sarcoidosis could have a bacterial pathogenesis. Three revisions of the paper are rejected by the journal "Sarcoidosis, Vasculitis and Diffuse Lung Diseases"  as having no potential interest for its readers.
 **2001 March** - The first early adopter, Elaine Emmi, begins the use of an ARB to treat her sarcoidosis.
@@ Line 89: / Line 89: @@
 broken links
 "[[http://catalogue.library.uwa.edu.au/search/?searchtype=X&searcharg=marshall+and+Trevor&searchscope=5&SORT=AZ&extended=0&SUBMIT=Search&searchlimits=&searchorigarg=Xmarshall+and+Trevor%26SORT%3DA|Modelling and simulation in diabetes care]]
+//[[http://www.sarcoidosis.it/home.html|Sarcoidosis, Vasculitis and Diffuse Lung Diseases]]//

home/arf/timeline.txt · Last modified: 09.14.2022 by 127.0.0.1